FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.